Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 31, 2014

View Archived Issues

Validation of PIM-1 inhibition as a treatment for KRas-driven NSCLC in mice

Spinal GlyT2 modulates spinal cord injury-induced spasticity in a rat model

Researchers find common genetic variant associated with cervical artery dissection

Anti-PD-L1 antibody efficacious against metastatic bladder cancer

Veliparib granted FDA orphan drug status

EB Pharma in-licenses Janssen farnesyl transferase inhibitor for HDV

FDA grants orphan drug status to OTL-38 for detecting ovarian cancer

Biotie Therapies begins phase IIa trial of SYN-120 in Parkinson's disease dementia

Dosing begins in phase I study of Kinex's KX2-361

Data presented on a novel MAPK pathway inhibitor for the treatment of colorectal cancer

Novastem treats first patient using mesenchymal and neural stem cell combination

Medtronic submits premarket approval application for SynchroMed II

Spectrum Pharmaceuticals submits NDA to FDA for Captisol-Enabled Melphalan

Corgenix Medical receives grants to support Ebola rapid test development

Determination of exosomal miRNAs as markers of multiple myeloma prognosis

Jiangsu Hengrui Medicine describes bisulfate salt of JAK inhibitor for rheumatoid arthritis

Researchers patent IL-1beta/IRAP chimeric proteins for inflammation

Janssen and Gilead amend and expand HIV single-tablet regimen development agreements

Alexion completes rolling BLA submission to the FDA for asfotase alfa

FDA approves Dyloject for pain management

EIT+ patents glycoconjugates for use as pertussis vaccines

University of Leicester patents cytolysin inhibitors

Bayer Schering Pharma describes TTK inhibitors

Nanjing Sanhome Pharmaceutical prepares anti-HCV nucleosides

VEGFR-2 inhibitors reported in Kala Pharmaceuticals patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...